Stem Cell Treatment Tested in Adults With Late-Stage AIDS
Tests mesenchymal stem cells against a saline placebo in adults with late-stage AIDS.
Plain-language title generated from the registry record
Registry title: Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage
Key facts
- Where
- Beijing, Shenzhen, and Shijiazhuang, ChinaSee the 4 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-65 with confirmed HIV infection and a CD4+T count below 500 cells/ul. It tests mesenchymal stem cells against a placebo (saline).
- Age
- 18 to 65 years
- Sex
- All genders
- Disease stage
- Confirmed HIV infection with a CD4+T count of less than 500 cells/ul at baseline; no serious AIDS-related events.
- Earlier treatment
- Cannot have taken hormones or other immune-suppressing drugs for a long time, or immune-suppressing or body-wide cell-killing drugs for more than 3 months before joining. Must agree not to receive other immunotherapies during the trial.
- Biomarker or test result
- CD4+T count less than 500 cells/ul at baseline. Viral load for CMV and EBV must not be more than 1000 copies/ML. HBV, HCV, HDV or HEV tests must not be positive.
Main reasons for not taking part
- HBV, HCV, HDV or HEV infection with a positive test
- HIV-2 infection
- Serious problems in organs such as kidney, heart, lungs, digestion, hormones, nerves or immune system, or tumors
- Pregnant, breastfeeding, or planning to have children
- Drug addiction within 6 months, or a positive urine drug test
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT05939167, who can take part
Where in China
- Beijing 302 HospitalBeijing, ChinaContact: Fu-Sheng Wang, DoctorTaking people
- Beijing YouAn HospitalBeijing, ChinaContact: Li-Jun Sun, DoctorTaking people
- Shenzhen Third People's HospitalShenzhen, ChinaContact: Fu-Xiang Wang, DoctorTaking people
- The Fifth Hospital of ShijiazhuangShijiazhuang, ChinaContact: Er-Hei Dai, DoctorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Cell Energy Life Sciences Group Co. LTD
- Trial code
- NCT05939167
- Record updated
- 12 August 2025
- Original description
The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for AIDS patients at late stage.Read full original descriptionShow less
A Double-blind, Randomized Placebo-controlled Clinical Trial to Investigate the Safety and Efficacy of Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage
The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for AIDS patients at late stage.
Inclusion: Confirmed HIV infection, aged 18-65, both genders; CD4+T count less than 500 cells/ul at baseline; No serious AIDS related events. 3. could understand and sign the informed consent form and comply with the requirements of this study; agree not to participate in other studies and not to receive other immunotherapies during the period of participation in this study.
Exclusion: received treatment of hormones or other immunosuppressive drugs for a long time; received immunosuppressive drugs or systemic cytotoxic drugs for more than 3 months before recruiting; drug addiction within 6 months, or the urine drug test is positive; have HBV/HCV/HDV/HEV infection, and the virological test is positive; have HIV-2 infection; have serious complications in organs including renal, circulatory, respiratory, digestive, endocrine, neural and immunological diseases and tumors; The viral load for CMV and EBV is more than 1000 copies/ML; with serious AIDS related or unrelated events; have poor compliance during treatment; participate in other clinical trials currently; pregnant, breastfeeding, or have fertility requirements; unable or unwilling to provide informed consents, or unable to comply with research requirements; Other serious situations that may hinder clinical trials.